Publications, Pharmaceutical

How pMDIs are transforming Asthma and COPD treatments

Pressurized metered dose inhalers have been used to treat asthma and COPD for over 60 years. However, the technologies within the pMDI container closure system and the drug and its formulation are very different and continue to evolve to meet patient needs, contain costs, and address changes in regulatory and environmental laws.  The immediate challenge to the Pharmaceutical industry however, is how to develop more sustainable pMDIs while at the same time, maintain patients adherence and compliance to their familiar treatment, lower the GWP of inhalers and to lower the overall carbon footprint of treatment.

This interview reviews some of these challenges and development timelines for new sustainable pMDIs as well as the discussion around dose counters in all future pressurized metered dose inhalers.

Download the publication on Dose and Delivery: How pMDIs are Transforming Asthma and COPD
Author(s): Chris Baron
12 Jul 2022

This article was taken from Pharmafile Summer 2022, page 22. Samedan Ltd

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More About pulmonary drug delivery expertise

This Might Also Be of Interest

18 Sep 2018

Aptar Pharma provides guidance on FDA regulatory framework for OINDPs

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
1 Jun 2018

Connected Medicine: Insights from Payers and Other Stakeholders

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation

Read More
1 Dec 2017

Connected Health – An Effective Solution to Improve Patient Adherence

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation

Read More
1 … 17 18 19

How Can We Help?

Back To Top